NuVasive (NASDAQ:NUVA) : Traders are bullish on NuVasive (NASDAQ:NUVA) as it has outperformed the S&P 500 by a wide margin of 1.48% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.13%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.42% in the last 1 week, and is up 3.12% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 26.71% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $61.29 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $57.54 and the 200 Day Moving Average price is recorded at $50.42.
The stock has recorded a 20-day Moving Average of 3.58% and the 50-Day Moving Average is 8.73%.
NuVasive (NASDAQ:NUVA): stock turned positive on Friday. Though the stock opened at $59.98, the bulls momentum made the stock top out at $61.29 level for the day. The stock recorded a low of $59.84 and closed the trading day at $60.82, in the green by 1.86%. The total traded volume for the day was 717,823. The stock had closed at $59.71 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Hannon Jason, officer (EVP, International) of Nuvasive Inc, had unloaded 14,534 shares at an average price of $57.92 in a transaction dated on June 15, 2016. The total value of the transaction was worth $841,809.
Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.